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Introduction
!
Endoscopic retrograde cholangiopancreatogra-
phy (ERCP) with endoscopic sphincterotomy (ES)
was first introduced in 1974 in Germany and Ja-
pan [1,2] and a few years later in the Nordic coun-
tries, as an alternative to open surgery with cho-
ledochotomy in the treatment of common bile
duct stones. It was mainly used in elderly patients
or patients with severe comorbidity, in whom
mortality after ERCP was reduced compared to
open surgery [3], whereas young and healthy
patients were still predominantly treated with
open surgical procedures. Since the introduction
of laparoscopic cholecystectomy, ERCP with ES,
with or without cholecystectomy, has become
the most common procedure in the treatment of
common bile duct stones worldwide. A conse-
quence of this alteration in therapeutic regime is
that an increased number of young patients, with
a long life expectancy, currently undergo ES.
Reports demonstrate the long-term adverse ef-
fects of ES. Interruption of the sphincter of Oddi
has been reported to cause overgrowth of bac-
teria [4] in the common bile duct resulting in cho-
langitis and recurrent stone formation [5]. Studies
also show an increased incidence of cholangiocar-
cinoma after ES, presumably due to the bacterial
overgrowth and chronic inflammation in the bile
ducts [5,6]. This is in agreement with other re-
ports concerning the development of malignan-
cies after open bilioenteric anastomoses [7,8],
and transduodenal sphincterotomy [9]. These
data prompted us to hypothesize that ES increases
the long-term risk of cholangiocarcinoma, which
we were subsequently able to test in a Swedish
nationwide population-based study of all 27708
patients registered for an ERCP for benign disease
in the Swedish inpatient registry, since the intro-
duction of ERCP in the 1970s until 2005 [10]. Our
results showed that, among the 12629 patients
who had undergone ES, the risk of cancer in the
bile ducts was not increased compared to the
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Background and study aims: Elevated long-term
risk of cholangiocarcinoma is reported after endo-
scopic sphincterotomy (ES), but in a previous
study we found a trend towards a decreased risk.
The aim of this study was to evaluate the associa-
tion in a larger cohort with a longer follow-up.
Patients and methods: Data concerning all pa-
tients having had an inpatient endoscopic retro-
grade cholangiopancreatography (ERCP) were
collected from the hospital discharge registries of
Finland and Sweden. Incident cases of malignancy
were identified through linkage to the nation-
wide Cancer Registries. Patients with a diagnosis
of malignancy, before or within 2 years of the
ERCP, were excluded. The cohorts were followed
until a diagnosis of malignancy, death or emigra-
tion, or end of follow-up (end of 2010). The rela-
tive risk of malignancy was calculated as stand-
ardized incidence ratio (SIR) compared with the
general population, inherently adjusting for age,
gender, and calendar year of follow-up.
Results: A total of 69925 patients undergoing
ERCP from 1976 through 2008 were included in
the pooled cohort. ES was performed in 40193
subjects. The risk of malignancy was elevated in
the total cohort (SIR=2.3; 95% confidence inter-
val [CI] 2.1–2.5) irrespective of whether ES was
performed or not. The SIRs diminished with dura-
tion of follow-up.
Conclusions: We found an elevated risk of malig-
nancy both in the bile ducts alone and in the bile
ducts, liver or pancreas together, after ERCP. The
risk was the same, regardless of whether ES had
been performed or not, so ES was unlikely to be
the cause, and a common carcinogenic exposure
previous to the ERCP procedure, possibly ductal
gallstone disease, was more likely.
non-ES group, but on the other hand, that there was a tendency
toward a decreased long-term risk of bile duct cancer in the ES
group. However, due to the small number of patients followed
for more than 10 years, our data did not have the statistical power
to address this question. In this study, we also found a decreased
risk of malignancy in patients who had had a cholecystectomy.
The primary aim of this population-based cohort study of all pa-
tients registered for an ERCP in the inpatient registries in Finland
and Sweden was to study the risk of malignancy in the bile ducts
in a larger cohort and with a longer follow-up. A secondary aim
was to study the relationship between severe common bile duct
stone exposure, which is a valid assumption for the entire ERCP
cohort irrespective of ES, and malignancy in the biliary tract.
Because of expected extensive misclassification between extra-
hepatic bile duct cancers and pancreatic cancer, as well as be-
tween intrahepatic bile duct cancers and liver cancer, both bile
duct cancer alone as well as bile duct cancer together with pan-
creatic and liver cancers, were used as outcome parameters.
Materials and methods
!
Registries, cohort and follow-up
We used data from the Finnish and Swedish hospital discharge
registers, in which discharge diagnoses and surgical procedures
are computerized for each hospitalization. Unique national regis-
tration numbers for each inhabitant are in use in both Finland
and Sweden, and we used them for identification. The coverage
of the registries is nearly 100% from 1986 and onwards [11,12].
The hospital discharge registries were introduced 1986 in Fin-
land and 1965 in Sweden, and the first ERCP procedurewas regis-
tered in 1976. We identified patients from 1986 to 2010 in Fin-
land and 1976 to 2010 in Sweden with at least one in-hospital
episode with a discharge procedure code for ERCP or endoscopic
sphincterotomy. In the ERCP group, patients with a code of ERCP
with or without biopsy and cholangioscopy were included while
the ES group included patients with codes of sphincterotomy,
extraction of stones, insertion of stent or nasobiliary drainage
(International Classification of Operations and Major Procedures,
codes 9014, UJK02, UJK05, UJK12, UJK15 for ERCP or 5388, 5394,
JKE 02, JKE 12, JKE 15, JKE 18, JKE 25, JKE 98 for ES or procedures
for which ES is normally a prerequisite). Using the national regis-
tration number, the patients identified with the procedure codes
listed abovewere linked to each country’s nationwide cancer reg-
istry, population registry, and migration registry for cancer out-
come ascertainment and censoring due to death and emigration,
respectively. A detailed description of the methods used has been
described elsewhere [13].
For further analyses, the total ERCP cohort for each country was
divided into two subgroups: (1) patients having at least one pro-
cedure code registration for ES or any other endoscopic biliary
procedures for which an ES is normally a prerequisite (Interna-
tional Classification of Operations and Major Procedures, codes
5388, 5394, JKE 02, JKE 12, JKE 15, JKE 18, JKE 25, JKE 98), and
(2) patients in the cohort without any procedure code registra-
tion for ES or any other endoscopic biliary procedure implying ES.
Those patients who had a diagnosis of malignant tumor in the
bile ducts, liver or pancreas (ICD-O-3 C22–25 in the Finnish
data and ICD7 155–157 in the Swedish data or corresponding
codes in the later classifications) at the time of the procedure or
within 2 years after it, were excluded from further analyses to
avoid selection bias, since the registered ERCP in these cases
may have been performed because of the tumor or due to symp-
toms caused by a tumor that was still undiagnosed. Considering
the poor prognosis of malignancies in the biliary tract, liver and
pancreas, it is highly unlikely that a tumor causing symptoms
would be diagnosed more than 2 years later. The cohorts were
then followed from entry (2 years after the procedure) until diag-
nosis of an outcome malignancy (primary malignant tumors in
the liver, bile ducts including ampullary region and pancreas,
but excluding gallbladder malignancy, ICD7 codes: 155 and 157,
but excluding 1551 and ICD10 codes C22.1, C24.0, C24.1, C24.8,
and C25), death, emigration or end of follow-up (31 December
2010), whichever occurred first.
The study was approved by the National Institute for Health and
Welfare in Finland and the Regional Research Ethics Committee
of Stockholm and Helsinki.
Statistical analyses
Several patients had ERCP or ES procedures registered more than
once. For each patient, every first-time procedure was regarded
as the index procedure for the corresponding cancer analyses. If
the first-time procedure included or implied ES, the patient’s
person-time was only included in the ES subgroup. If a patient’s
first procedure was non-ES or ES-implying followed by a subse-
quent procedure implying ES, this patient had two index proce-
dures: one without ES, with person-time counted from 2 years
after the procedure until the subsequent ES procedure (i. e. cen-
sored at the time of the ES procedure); and another one after
which person-time was counted in the ES subgroup from 2 years
after the ES procedure. However, for the whole ERCP group, per-
son-time was counted from 2 years after entry until the occur-
rence of cancer, death, emigration or end of follow-up, irrespec-
tive of ES procedure (●" Fig.1). Thus the total person-time in the
whole ERCP cohort was more than the sum of the person-time
experienced by the two subgroups.
The standardized incidence ratio (SIR), the ratio of the observed
to the expected number of malignancies, was used to calculate
relative risk. The background cancer incidence rates for the gen-
eral Swedish and Finish populations were provided by the
national cancer registries in the corresponding country, which
was the same as the source for linkage to identify cancer cases
Procedure Entry End of follow-up2 years
Non ES 
procedure Entry
ES procedure 
and end of 
follow-up non 
ES time
Entry End of follow-up2 years Non ES time 2 years ES time
Fig.1 Calculation of follow-up time in patients with one or several procedures. End of follow-up was 31 December 2010, a diagnosis of malignancy, death,
emigration or second procedure.
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during follow-up. The expected number of cancers was calculat-
ed by using the sex, calendar, age, and country-specific incidence
rates. The standardized incidence ratios are inherently adjusted
for confounding by age at follow-up, gender, and calendar year
of follow-up.
To calculate the pooled SIR, we first combined the number of ob-
served cancers,∑O, by summing data from the two countries, and
the combined number of expected cancers, ∑E, was determined
in a similar way. The pooled SIR was calculated as ∑O/∑E. The
95% confidence intervals (CIs) for the pooled SIR were deter-
mined by assuming a Poisson distribution of the observed num-
bers of cancer. Results using the weightedmeta-analysis were es-
sentially identical with those using the pooled method, and tests
for heterogeneity using the chi-squared test as well as I2 statistics
demonstrated that the inconsistencies across the two studies
were minor (χ2=0.19, df=1, P=0.66; I2=0%). Therefore, we just
present the data from the pooled analyses [14–16]. Further ana-
lyses were stratified by duration of follow-up (2–4, 5–9, ≥10
years). The excess absolute risk, i. e. difference between observed
and expected number of cases divided by person-years (∑(O-E)/
∑person-years×100000), was also calculated.
A two-sided P value less than 0.05 was considered to be statisti-
cally significant. All analyses were conducted with SAS statistical
software, version 9.4 (Cary, North Carolina, United States).
Results
!
The final cohorts of patients having undergone ERCP, for diagnos-
tics or therapy of non-malignant diseases, included 16575 pa-
tients in Finland and 53350 patients in Sweden contributing to
a total of 506998 person-years of follow-up.●" Table1 shows the
steps for selection of patients from the total cohorts including all
ERCP procedures to the eligible final benign disease ERCP cohorts.
The sums of the ES and non-ES groups are larger than the all
ERCP groups, because a number of patients had an ERCP without
ES before a subsequent ERCP with ES. Of these, 784 did not have a
diagnosis of malignancy at the time of the first or second index
procedures or within 2 years thereafter, and were thus counted
in both subgroups.
The general characteristics of the cohorts and the number of ob-
served malignancies 2 years or more after the index procedure
are included in●" Table2. The mean age at entry, 2 years after the
procedure, was 66 years in Sweden and 64 years in Finland. There
was a predominance of women in both countries. The mean fol-
low-up time was 7.3 years in the all ERCP cohort, but was shorter
among patients who had undergone an ES. Bile duct malignancy
was infrequent and despite the large size of the cohort, the num-
ber of bile duct malignancies in the studied populationwas low.
The risk of developing malignancy in the bile ducts, liver, or pan-
creas, explicitly excluding gallbladder malignancy, was increased
in the all ERCP cohorts, the ES cohorts, and the ERCP without ES
cohorts in both Finland and Sweden (data not shown). In the
pooled all ERCP cohort, the risk wasmore than twofold compared
to the general national populations (SIR 2.3; 95%CI 2.1–2.5).
Likewise, it was increased in the pooled ES subgroup (SIR 2.2;
95%CI 2.0–2.5) and almost the same in the non-ES subgroup
(SIR 2.1; 95%CI 1.9–2.3) (●" Table3). The relative risk of bile duct
malignancy alone, was increased nearly four times (SIR 3.9; 95%
CI 3.3–4.5) in the pooled all ERCP cohort, and tended to be higher
in the ES cohort (SIR 4.3; 95%CI 3.5–5.5) than in the cohort with-
out ES (SIR 2.7; 95%CI 2.0–3.5) (●" Table3).
The SIR of malignancy of the bile ducts, liver, or pancreas was
much elevated in the first two years after the procedure at 69.2
(95%CI 66.8–71.6), but then decreased gradually with increasing
follow-upduration. In the pooled all ERCP cohort in the period be-
tween 2 and 5 years after the index ERCP, the SIR was 3.0 (95%CI
2.7–3.5) and decreased to 1.9 (95%CI 1.6–2.2) for 10 years and
Table 1 Size of cohorts of patients having undergone ERCP, ERCP with ES
and ERCP without ES in Finland and Sweden.
All ERCP1 ES1 ERCP without
ES1
Total 117 416 72331 49896
Operation date before entry
(1976-01-01 for Sweden
and 1986-01-01 for Finland)
14 2 13
Error in registration 1645 1121 580
Cancer diagnosis2 before entry 8583 5380 3443
Follow-up less than 2 years 37 249 25635 15344
Eligible 69 925 40193 30516
ERCP, endoscopic retrograde cholangiopancreatography; ES, endoscopic sphincter-
otomy.
1 The sum of the ES group and ERCP without ES group was more than the whole ERCP
cohort, since some patients contributed person-time to both groups.
2 Diagnosis of malignant tumor in the bile ducts, liver or pancreas.
Table 2 Selected characteristics and number of patients developing malig-
nancy more than 2 years after ERCP with or without ES in Finland and Sweden.
All ERCP
(n=69925)
ES
(n=40193)
ERCP without
ES
(n=30516)
Mean (± SD) age at entry,
years
65.4 ± 17.7 67.4 ± 17.7 62.7 ± 17.8
Sex (% male) 41.8 40.8 43.2
Mean of follow-up, years 7.3 5.3 9.4
Person-years at risk 506 998 162682 238561
Malignancy of bile ducts,
liver, or pancreas exclud-
ing gallbladder, cases
670 289 330
Malignancy of bile ducts
(ICD-7 155, excluding
1550 and 1551)
150 79 55
Malignancy of pancreas
(ICD-7 157)
309 139 146
ERCP, endoscopic retrograde cholangiopancreatography; ES, endoscopic sphincter-
otomy.
Table 3 Pooled SIRs and their 95% confidence intervals (CI) for diagnosis of
malignancies 2 years or more after ERCP with or without ES on a benign indi-
cation.
All ERCP
(n=69 925)
ES
(n=40 193)
ERCP without
ES
(n=30 516)
SIR (95%CI) SIR (95%CI) SIR (95%CI)
Malignancy of the bile
ducts, liver, or pancreas
excluding gallbladder
2.3
(2.1–2.5)
2.2
(2.0–2.5)
2.1
(1.9–2.3)
Malignancy of the
bile ducts
3.9
(3.3–4.5)
4.4
(3.5–5.5)
2.7
(2.0–3.5)
Malignancy of the
pancreas
1.8
(1.6–2.0)
1.7
(1.5–2.1)
1.5
(1.3–1.8)
ERCP, endoscopic retrograde cholangiopancreatography; ES, endoscopic sphincter-
otomy; SIR, standardized incidence ratio.
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moreafter the indexERCP. The excess absolute riskswere similarly
decreasing with follow-up duration (●" Table4). The analyses
stratified by ES showed a similar pattern, with decreasing point-
estimates for relative risks and absolute risks with longer follow-
up. The risk of developing cancer in the bile ducts after ERCP, with
or without ES also decreased with length of follow-up, but since
cholangiocarcinoma is a rare tumor, the confidence intervals are
wide despite the large size of the cohort (●" Table5).
Discussion
!
This large, population-based cohort study was designed primari-
ly to investigate the risk of developing malignancy in the bile
ducts after ES in a large cohort with a long follow-up, a concern
raised in other publications [5,17,18]. We demonstrate here a
fourfold significantly increased risk of malignancy in the bile
ducts alone after ERCP, and not significantly higher after ES.
Among patients who had undergone ERCP, with or without ES,
we found a twofold increased risk of malignancy in the bile ducts,
liver, or pancreas. In both the ES and non-ES groups, the absolute
excess risks as well as the SIRs of developing a malignancy in the
bile ducts, liver, and pancreas together, decreased with increas-
ing length of follow-up.
The strengths of our study include the population-based cohort
design with follow-up of a vast majority of patients having
undergone ERCP procedures in Finland and Sweden during the
study-period. Another strength is the close to complete follow-
up of the patients in the registries used in this study, avoiding dif-
ferential misclassification and thus ensuring high internal valid-
ity. The consistent results in two separate countries could add to
the reproducibility. Furthermore, the large size of the cohort
provided adequate statistical power, which enabled us to analyze
the relative risks of the studied malignancies in the bile ducts,
liver, and pancreas after stratification for ES.
A limitation of this study may be that cancer of the bile ducts is a
rare malignancy with a low expected incidence even in a large
pooled cohort, limiting the subgroup analyses of cancer risk by
follow-up duration. The mean follow-up time was shorter in the
ES subgroup than in the ERCP without ES group in both the Fin-
nish and Swedish cohorts, as a result of the fact that ES was not
performed at the beginning of the period. However, the size of
the pooled cohort gives an opportunity to interpret data with a
better precision than in previous studies. The risk of misclassifi-
cation between intrahepatic cholangiocarcinoma and liver can-
cer, as well as between extrahepatic cholangiocarcinoma and
pancreatic cancer must be acknowledged. Therefore, both bile
duct malignancy alone as well as bile duct malignancy together
with liver and pancreatic malignancies, were used as outcomes
in spite of the fact that our hypothesis primarily concerned chol-
angiocarcinoma of the intrahepatic and extrahepatic bile ducts.
The influence of this type of misclassification is predictable and
thus tolerable given the use of both outcomes described above.
This study demonstrates an approximately fourfold increase in
the risk of malignancy in the bile ducts alone and a twofold
increase in the bile ducts, liver and pancreas together, in a large
cohort of patients followed up after ES. This increased risk is not
likely to be caused by the ES procedure in itself. If that were the
case, one would expect to identify a non-elevated risk of tumors
at the beginning of the follow-up period and then a gradual in-
crease over time. On the contrary, in this cohort, both in the ES
subgroup and in the non-ES subgroup, the relative risk of malig-
nancy was greatest at the beginning of follow-up, i. e. between 2
and 5 years after the index procedure.
In a study of the long-term consequences of ES by Tanaka et al.
[5], 410 patients were followed on average for 10 years after ES,
and carcinoma in the biliary tract was found in eight patients,
three of them late, giving a marked elevated risk of malignancy
both in the short and long term, a finding that was attributed to
the ES. The result of this study differs from ours by showing a
much higher risk of development of carcinoma in the biliary tract,
but is based on a much smaller cohort with a higher risk of ran-
dom error. Fujimoto et al. [17] reported a long-term risk of malig-
nancy in the biliary system, but predominantly gallbladder can-
Table 4 Pooled SIRs with their 95% confidence intervals (CI) for developing malignancy in the bile ducts, liver, or pancreas after ERCP, with or without ES, by
duration.
All ERCP (n=69925) ES (n=40193) ERCP without ES (n=30516)
Years after
procedure
E O SIR (95%CI) Excess ab-
solute risk1
E O SIR (95%CI) Excess ab-
solute risk1
E O SIR (95%CI) Excess ab-
solute risk1
2–4 75.7 230 3.0 (2.7–3.5) 122.8 42.9 131 3.1 (2.6–3.6) 125.9 33.4 97 2.9 (2.4–3.5) 112.2
5–9 122.6 266 2.2 (1.9–2.4) 68.1 61.0 123 2.0 (1.7–2.4) 61.2 61.4 124 2.0 (1.7–2.4) 57.4
≥10 92.8 174 1.9 (1.6–2.2) 47.6 26.2 35 1.3 (0.9–1.9) 19.5 64.6 109 1.7 (1.4–2.0) 36.4
ERCP, endoscopic retrograde cholangiopancreatography; ES, endoscopic sphincterotomy; SIR, standardized incidence ratio.
1 Calculated from (O–E) / person-years×100000.
Table 5 Pooled SIRs with their 95% confidence intervals (CI) for developing malignancy in the bile ducts after ERCP, with or without ES, by duration.
All ERCP (n=69925) ES (n=40193) ERCP without ES (n=30516)
Years after
procedure
E O SIR (95%CI) Excess ab-
solute risk1
E O SIR (95%CI) Excess ab-
solute risk1
E O SIR (95%CI) Excess ab-
solute risk1
2–4 10.1 64 6.4 (4.9–8.1) 42.9 5.9 40 6.8 (4.8–9.2) 48.8 4.2 25 5.9 (3.8–8.7) 36.6
5–9 16.3 56 3.4 (2.6–4.4) 18.8 8.4 32 3.8 (2.6–5.3) 23.3 7.9 17 2.1 (1.3–3.4) 8.3
≥10 12.3 30 2.4 (1.6–3.5) 10.4 3.6 7 1.9 (0.8–4.0) 7.5 8.4 13 1.5 (0.8–2.6) 3.8
ERCP, endoscopic retrograde cholangiopancreatography; ES, endoscopic sphincterotomy; SIR, standardized incidence ratio.
1 Calculated from (O–E) / person-years×100000.
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cer, of 3.1% after ES, a rate they concluded to be comparable with
the incidence of gallbladder cancer found in patients with gall-
stone disease.
On the other hand, in a previously published population-based
study of 992 patients who underwent ES at six different hospi-
tals, Karlsson et al. found no increase in the risk of cancer in the
liver, bile ducts, or pancreas at follow-up 1 year or more after the
procedure [19]. This study, also performed in Sweden, is based on
a regional subgroup of our own study cohort.
In a large population-based Danish study, Mortensen et al. [20]
compared more than 20000 patients undergoing ERCP with or
without ES and found a high incidence of cholangiocarcinoma in
both groups in the first year after the procedure but a decreasing
incidencewith length of follow-up, the same result as in the pres-
ent study, and concluded a lack of causal association between ES
and cholangiocarcinoma.
Our study shows an increased risk of malignancy after ERCP but
since the risk diminisheswith length of follow-up, it is likely to be
caused by some common exposure before the ERCP procedure, a
conclusion well in line with the Danish findings and the result of
our previous study. By far the most likely candidate is gallstone
disease, in particular, ductal gallstone disease. In our previous
study [10], based on a subgroup of the present cohort, we found
that patients who had ever had a cholecystectomy had a lower
risk of malignancy, irrespective of ES, a finding that could support
this theory. We also calculated the risk of lung cancer as an esti-
mate for potential bias of tobacco smoking, a known risk factor
for pancreatic carcinoma, and found no elevated risk compared
to the general population.
All patients with a diagnosis of malignancy in the biliary tract,
liver, or pancreas at the time of the index procedure, or within 2
years after it, were excluded from the cohort. Patients having un-
characteristic abdominal discomfort could have been subject to
ERCP on the assumption of gallstone disease when the symptoms
were instead caused by an undiagnosed malignancy explaining
the extremely elevated SIRs. We also excluded all patients who
were diagnosed with gallbladder malignancy since gallbladder
carcinoma is known to be strongly associated with gallstone dis-
ease [21], a condition likely to be very common among patients
having had an ERCP without a malignant diagnosis.
The risk of malignancy is highly elevated 2 years after ERCP. It is
unlikely to be explained by a preexisting undiagnosed cancer at
the time of the index procedure, considering the poor prognosis
of symptom-generating malignancies in the area. One possible
mechanism by which ductal gallstones could cause the high risk
of malignancy observed during this part of the follow-up, could
be that they may have started a slow, initially purely inflamma-
tory but subsequently carcinogenic, process before they were re-
moved and that the process continued after removal of the
stones.
In conclusion, this study shows an elevated risk of malignancy
both in the bile ducts alone and in the bile ducts, liver or pancreas
together, after ERCP. The risk is not influenced by including ES so
ES or any other part of the procedure is unlikely to be the cause.
The elevated risk of malignancy is more likely to be caused by
some other carcinogenic exposure prior to the ERCP procedure,
possibly ductal gallstone disease.
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